Trial · NCT02080624
Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome
NCT02080624, Phase 2, Completed, Clinica Universidad de Navarra, Universidad de Navarra
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome. Trials, record NCT02080624. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02080624
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome
- NCT number
- NCT02080624
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 23 participants, actual
- Lead sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
- Conditions
- Sturge- Weber Syndrome
- Interventions
- Drug: Topical Rapamycin
- First posted
- 2014-03-06
- Last updated
- 2014-03-06
- Other registries' IDs
- eudract:2010-024078-20
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in morphologic, chromatographic and spectrometric scores at week 6 | Baseline, Week 6 | Change Outcome Measure |
| Primary | Change from baseline in morphologic, chromatographic and spectrometric scores at week 12 | Baseline, Week 12 | Change Outcome Measure |
| Primary | Change from baseline in morphologic, chromatographic and spectrometric scores at week 18 | Baseline, Week 18 | Change Outcome Measure |
| Primary | Histological response at 12 weeks. | 12 weeks | Efficacy Outcome Measure |
| Secondary | Adverse events at baseline | At the beginning of the intervention | |
| Secondary | Adverse events at 6 weeks | 6 weeks after the beginning of the intervention | |
| Secondary | Adverse events at 12 weeks | 12 weeks after the beginning of the intervention | |
| Secondary | Adverse events at 18 weeks | 18 weeks after the beginning of the intervention | |
| Secondary | Total blood cholesterol level (mg/dL) at baseline. | At the beginning of the intervention | |
| Secondary | Total blood cholesterol level (mg/dL) at 6 weeks. | 6 weeks after the beginning of the intervention |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02080624
GET https://conductscience.org/api/trials/v1/NCT02080624/registered